The Miyoshi America $20 Million Talc Trust: What Mesothelioma and Ovarian Cancer Patients Need to Know
You are reading this because you, or someone you love, has been diagnosed with mesothelioma or ovarian cancer, and you have learned that a company called Miyoshi America just created a twenty-million-dollar trust through bankruptcy court to pay people like you. You may be sitting at a kitchen table at two in the morning with a pathology report in one hand and a phone in the other, trying to understand whether this trust is your answer or a trap. We are going to tell you the truth about both — because the most important thing you can learn right now is that this trust is probably not your only option, and in many cases it should not be your first one.
The trust is real. A Texas bankruptcy judge confirmed it, ninety-nine percent of existing claimants voted to accept it, and not a single objection was filed by the deadline. It is historic — the first prepackaged talc reorganization in United States bankruptcy history. But twenty million dollars, split among every current and future person who files a claim against Miyoshi America for asbestos-contaminated cosmetic talc, is a modest pool. Traditional asbestos trusts range from hundreds of millions to several billion dollars. This one is twenty million. And the company that supplied the ingredient is only one piece of a supply chain that runs from a mine in the earth to a bottle on a store shelf — most of the companies in that chain are not in bankruptcy, were not discharged, and remain fully answerable in court.
We are The Manginello Law Firm, PLLC — Attorney911, and we handle toxic tort cases involving asbestos, mesothelioma, and the corporations whose products caused them. We are writing this page as the legal education and resource document we would want our own family to have if the diagnosis were theirs. Everything that follows is legal information, not legal advice — but it is legal information from a firm that has spent more than twenty-seven years in courtrooms fighting for injured people, and from attorneys who know, from the inside, how insurance companies value and defend these claims.
What the Miyoshi America Trust Actually Is
Miyoshi America Inc. is a Connecticut-based company that supplied cosmetic talc ingredients to manufacturers of consumer products — the companies whose names you would recognize on a store shelf. Miyoshi did not make the finished powder or the makeup. It supplied the raw talc that went into them. The company faced a growing number of lawsuits from people diagnosed with mesothelioma and ovarian cancer who alleged that the talc Miyoshi supplied was contaminated with asbestos and that breathing or applying that talc over years caused their disease.
Miyoshi has never been found liable by any court. It denies that its products ever contained asbestos. But it characterized the volume of litigation as financially unsustainable — and rather than keep defending itself case by case, it negotiated a prepackaged Chapter 11 bankruptcy plan. “Prepackaged” means the company reached an agreement with its creditors — specifically, the law firms representing roughly ninety percent of current claimants, plus a future claimants representative whose sole job is to protect people not yet diagnosed — before it ever filed the bankruptcy petition. Six months of negotiation produced a plan that transfers all of Miyoshi’s current and future talc-related liability to a trust funded by nineteen million dollars in cash and a one-million-dollar promissory note.
The judge who confirmed the plan praised the process, calling it a landmark and emphasizing that the plan offers finality and certainty for claimants while allowing the company to continue operating and preserving jobs. The May nineteenth objection deadline passed without a single objection — an extraordinary level of consensus in mass-tort bankruptcy.
Here is what that means in plain terms: if you have a claim against Miyoshi America for mesothelioma or ovarian cancer allegedly caused by asbestos-contaminated cosmetic talc, the trust is the entity that will eventually process your claim. Your direct lawsuit against Miyoshi is channeled to the trust. You cannot sue Miyoshi in regular court anymore — the bankruptcy’s channeling injunction directs all current and future Miyoshi talc claims to the trust, which will administer them under trust distribution procedures that have not yet been finalized as of this writing.
Why the Trust Is Probably Not Your Only Option
This is the single most important section on this page, and it is the one most other sources will not tell you.
Miyoshi America was an ingredient supplier. It sold talc to other companies. Those other companies — the downstream cosmetic manufacturers — incorporated Miyoshi’s talc into finished consumer products: body powders, baby powders, face powders, eye shadows, blushes, and other cosmetic items that millions of people used daily for years or decades. Those downstream manufacturers are not in bankruptcy. Their liability was not discharged. They remain fully suable in court, and they carry their own insurance and corporate assets.
When a person is diagnosed with mesothelioma and has a history of using cosmetic talc products, the question is not just “which supplier provided the talc” but “which finished product did this person use, who made it, and what did that manufacturer know about the possibility of asbestos contamination?” The manufacturer that put the talc into a product and sold it to a consumer without testing it for asbestos, without warning the consumer that cosmetic talc may contain asbestos fibers, and without sourcing from asbestos-free talc deposits — that manufacturer faces independent product-liability exposure that the Miyoshi bankruptcy does not touch.
“Toxic-tort statutes of limitation nationwide generally follow a discovery rule under which the clock begins at diagnosis rather than exposure — critical given mesothelioma’s 20-50 year latency.”
That principle — the discovery rule — is your lifeline. It means the deadline to file a lawsuit usually does not start ticking on the day you used the talc thirty years ago. It starts when you discovered, or reasonably should have discovered, that you were sick and that the talc may have caused it. For most mesothelioma patients, that date is the date of diagnosis. For ovarian cancer patients, the analysis is similar but can involve additional questions about when the connection to talc was or should have been identified.
The trust will accept claims. But a trust claim alone, against a twenty-million-dollar shared pool, will likely produce a payout that is a fraction of what full tort litigation against solvent defendants could yield. Comparable asbestos trusts typically pay five to twenty-five percent of the liquidated value of a claim — meaning a claim liquidated at one million dollars might pay fifty thousand to two hundred and fifty thousand dollars from the trust. Meanwhile, mesothelioma verdicts against solvent manufacturers in favorable venues have reached eight figures. The trust is one avenue. It is very rarely the only avenue. And signing a release that forecloses all other claims before every defendant in the supply chain has been identified is the single most dangerous thing a claimant can do in this process.
The Science: How Cosmetic Talc Becomes a Killer
Talc and asbestos are not separate materials that sometimes accidentally mix. They are minerals that form together in the earth under similar geological conditions. Talc deposits and asbestos deposits co-occur — they are found in the same geological formations, mined from the same areas, and separated only by the quality of the mining, milling, and purification process. This is not a theory; it is mineralogy. The geological co-occurrence of talc and asbestos is a well-documented phenomenon that has been understood by geologists and industrial hygienists for decades.
When a talc mine extracts ore from a formation that also contains asbestos, the resulting talc can be contaminated with asbestos fibers. Those fibers — microscopic, durable, and physically sharp — do not dissolve in the body. When a person applies cosmetic talc to their skin, the powder releases airborne particles. If those particles include asbestos fibers, the person inhales them. The fibers travel into the lungs and, for some products used in the genital area, may also migrate to the ovaries through the reproductive tract.
The asbestos fibers lodge in the pleura — the thin membrane that lines the lungs — or in the peritoneum, the lining of the abdomen. The body cannot break them down. Over decades, the chronic physical irritation and the chemical toxicity of the fibers cause genetic damage to the cells in those linings. That damage can eventually produce mesothelioma, a cancer of the pleura or peritoneum that is essentially signature to asbestos exposure. The same fibers, reaching the ovaries through ascending migration, have been associated with ovarian cancer in women who used talc-containing genital powders for extended periods.
The latency period — the time between first exposure and disease — is twenty to fifty years for mesothelioma. A woman who used cosmetic talc daily in her twenties and thirties may not develop mesothelioma until her sixties or seventies. A man who used after-shave talc in the 1970s may be diagnosed today. The long latency is why the discovery rule matters so much: most patients have no idea their cancer is connected to a product they used half a lifetime ago until a physician or a lawyer makes the connection.
The Environmental Protection Agency finalized a ban in 2024 on ongoing uses of chrysotile asbestos — the first asbestos ban in decades — reflecting the broader regulatory recognition that no level of asbestos exposure is safe. The Food and Drug Administration, which regulates cosmetics under the Federal Food, Drug, and Cosmetic Act, historically did not require premarket approval of cosmetic ingredients. The Modernization of Cosmetics Regulation Act of 2022 expanded the FDA’s authority over cosmetics, including mandatory facility registration, cosmetic product listing, adverse-event reporting, and safety substantiation requirements — but for decades, cosmetic talc entered the market without independent government testing for asbestos contamination.
The Medicine: What These Diseases Do to a Human Being
Mesothelioma is a uniformly fatal malignancy. There is no cure. Median survival from diagnosis is twelve to twenty-one months. The disease arises in the pleura — the lining of the lungs — or less commonly in the peritoneum, the lining of the abdomen. It progresses by spreading across the surface of the lung and into the chest wall, causing progressive respiratory failure, severe pain, and the accumulation of fluid in the chest cavity that must be drained repeatedly.
Treatment is multimodal and grueling. Patients may undergo surgical resection — sometimes an extrapleural pneumonectomy, which removes the entire lung, the pleura, the diaphragm, and the pericardium on one side of the chest — combined with heated chemotherapy delivered directly into the chest cavity during surgery, followed by radiation therapy. Even with aggressive treatment, the disease almost always recurs. Medical expenses alone frequently exceed five hundred thousand to one million dollars. The patient loses the ability to work, to breathe without assistance, and eventually to perform basic daily activities. The family watches a person they love suffocate slowly over months.
Ovarian cancer presents a different but equally severe profile. Treatment typically involves surgical removal of the ovaries, fallopian tubes, and often the uterus, followed by platinum-based chemotherapy. Recurrence is common. Five-year survival rates vary significantly by the stage at diagnosis — early-stage ovarian cancer has a far better prognosis than disease that has already spread beyond the pelvis at the time of detection. The connection between cosmetic talc use in the genital area and ovarian cancer has been the subject of extensive epidemiological study, and the International Agency for Research on Cancer has classified perineal use of talc-based body powder as “possibly carcinogenic to humans” (Group 2B).
For both diseases, the proof problem is significant. Mesothelioma, while essentially signature to asbestos, requires the plaintiff to identify which asbestos-containing product caused the exposure — and in cosmetic talc cases, that means identifying specific brands, specific products, and specific periods of use, often decades after the fact. Ovarian cancer has multiple risk factors, and the defense will argue that the cancer was caused by genetics, hormones, or other environmental factors rather than talc. These are not simple cases. They require expert testimony from oncologists, pathologists, industrial hygienists, and geologists to establish the exposure pathway and the causal connection.
For families who have lost someone to mesothelioma or ovarian cancer, we handle wrongful death claims that seek accountability from every entity in the supply chain — not just the one that filed for bankruptcy.
The Defendant Map: Who Else May Be Responsible
Miyoshi America is the company that filed for bankruptcy and created the trust. But a cosmetic talc case has a supply chain, and every link in that chain is a potential defendant.
Miyoshi America Inc. — the ingredient supplier. Its liability has been transferred to the twenty-million-dollar trust. Claims against Miyoshi are channeled to the trust.
Miyoshi’s parent company — participated in the bankruptcy negotiations and contributed to the settlement structure. Under corporate law, a parent company that exercises sufficient control over a subsidiary’s operations, safety decisions, or litigation strategy can face direct liability through alter-ego or veil-piercing theories. Whether the parent is reachable depends on discovery — the internal communications, the financial relationships, the degree of operational control. This is a target for investigation, not a given.
Downstream cosmetic manufacturers — these are the companies that purchased talc from Miyoshi, incorporated it into finished consumer products, and sold those products to the public. They are not in bankruptcy. Their liability is not discharged. They face independent product-liability claims for design defect (putting asbestos-contaminated talc into a product), failure to warn (not telling consumers the talc may contain asbestos), manufacturing defect (failing to control contamination during production), and negligence (failing to test their talc for asbestos using adequate analytical methods). These companies carry their own insurance — often far more than the twenty-million-dollar trust pool.
Talc mining and extraction entities — the companies that extracted the talc from the earth. Asbestos co-occurrence is a geological fact, and mines that supply cosmetic talc from formations known to contain asbestos are the origin of the contamination pathway. If the mine knew or should have known its talc was contaminated, it faces its own liability.
Retailers — in some jurisdictions, the companies that sold the finished products to consumers face product-liability claims, particularly if they knew or should have known about the asbestos contamination risk.
The trust is one defendant. The supply chain is the case. A claimant who files only with the trust, without identifying the downstream manufacturers and other entities whose products they actually used, may leave the majority of their potential recovery on the table.
The Evidence Clock: What Records Exist and How Fast They Disappear
Toxic tort cases are built from evidence that is decades old and deteriorating. Every category of proof in a cosmetic talc case is on a clock — and some of those clocks have already run out for certain products and certain companies.
Retained product samples and batch records — the single most powerful evidence in a talc-asbestos case is a physical sample of the actual product the claimant used, tested with transmission electron microscopy or X-ray diffraction to prove the presence of asbestos fibers. But products are discontinued, reformulated, or destroyed. Retained samples degrade over time. A bottle of body powder from the 1980s may still exist in someone’s bathroom cabinet — or it may have been thrown away decades ago. The moment a case is contemplated, the family should search for any remaining product containers, lot numbers, and purchase records.
Internal corporate communications and testing records — the documents that reveal whether a manufacturer knew its talc contained asbestos, what testing it performed or omitted, and whether it considered or implemented asbestos-free sourcing. These are the documents that drive punitive damages and fraudulent-concealment theories. But corporate retention policies may permit destruction, and bankruptcy transitions can result in records being transferred, lost, or rendered inaccessible. Employee turnover accelerates the loss of institutional knowledge — the people who knew what the company tested in 1985 may no longer be alive or reachable.
Supply chain documentation — mining sources, processing records, shipping manifests. These documents link the talc in a specific finished product to a specific geological formation known for asbestos co-occurrence. Supplier records can be lost in corporate transitions, mergers, or business closures. The geological source data — which mine supplied which talc to which manufacturer — may become inaccessible as companies reorganize.
Downstream manufacturer formulations and ingredient sourcing records — the documents that establish which finished products contained Miyoshi-supplied talc and whether consumers were warned of potential asbestos content. Product reformulation and corporate record-retention policies may have eliminated historical formulation data. A manufacturer that reformulated its product in 2000 may not have retained the ingredient sourcing records from 1985.
Claimant exposure histories and medical records including pathology blocks — the specific causation evidence that links the claimant’s mesothelioma or ovarian cancer to cosmetic talc exposure. Tissue analysis for asbestos fiber burden can provide direct physical evidence of the fibers in the patient’s body. But memory degrades over the decades-long latency period. Family witnesses who could corroborate product use pass away. Hospital pathology blocks — the preserved tissue samples from biopsy or surgery — are discarded by hospitals after their statutory retention periods expire, which in many states is a matter of years, not decades.
FDA communications and regulatory correspondence — demonstrates regulatory awareness of talc-asbestos concerns and any agency actions or warnings relevant to the product class. These records remain generally accessible, but the regulatory framework is in transition under MoCRA, which may alter FDA record-keeping systems.
The preservation letter — a formal demand that a company freeze specific records and not destroy them — is the first weapon in a toxic tort case. It goes out the day you call. Not the month. Not the quarter. The day. Because once a document is legally destroyed under a retention policy, it is gone, and the only remedy is an adverse-inference instruction that tells the jury they may assume the missing record was as bad as the plaintiff says — a powerful but imperfect substitute for the document itself.
For mesothelioma and toxic exposure cases, we have specific experience — our firm has fought for workers exposed to asbestos and benzene at refineries in the Gulf Coast industrial corridor, and the principles of evidence preservation, exposure reconstruction, and causation proof are the same whether the asbestos came from a refinery pipe or a cosmetic powder bottle.
What a Case Is Actually Worth
Honesty about case value is not pessimism — it is the thing that lets a family plan. Here is the straight truth about what the Miyoshi trust and the broader supply chain litigation can and cannot provide.
Trust-only claims. The twenty-million-dollar trust is funded by nineteen million in cash and a one-million-dollar promissory note. That pool is shared among all current and future claimants — every person who has already filed a claim plus every person who will be diagnosed with mesothelioma or ovarian cancer and file a claim in the decades to come. Traditional asbestos trusts typically pay five to twenty-five percent of the liquidated claim value. If that range holds for the Miyoshi trust, a mesothelioma claim liquidated at one million dollars might produce a trust payment of fifty thousand to two hundred and fifty thousand dollars. An ovarian cancer claim, typically liquidated at a lower value, would produce less. The trust’s payment percentage and claims matrix have not yet been finalized, so these are estimates based on comparable asbestos-trust structures, not confirmed figures.
Litigation against solvent non-debtor defendants. A claimant who can identify specific downstream products, establish a robust exposure history, and pursue the manufacturers and retailers that sold those products retains full tort-value potential. Mesothelioma verdicts in favorable venues have reached eight figures — five million to fifteen million dollars and beyond — particularly where the evidence shows the manufacturer knew or should have known about asbestos contamination and failed to test or warn. Ovarian cancer verdicts against talc manufacturers have also been substantial, though the causation evidence is more contested and results vary more widely by jurisdiction.
The full picture. A comprehensive case strategy files the trust claim promptly — to secure a distribution position before the finite pool is depleted by future claimants — while simultaneously pursuing litigation against every solvent defendant in the supply chain. The trust payment is a floor. The tort litigation is the ceiling. A family that files only with the trust gets the floor. A family that identifies every defendant and litigates aggressively gets the floor and the ceiling.
Damage categories in tort litigation. A mesothelioma case seeks compensation for: past and future medical expenses (often five hundred thousand to one million dollars or more); lost wages and lost earning capacity; pain and suffering — the severe, progressive respiratory failure and chest-wall invasion that characterizes the disease’s final months; loss of consortium and companionship for the spouse and family; and, where the evidence supports it, punitive damages designed to punish conduct that showed conscious disregard for consumer safety. In wrongful death cases, the estate and beneficiaries seek the losses the family suffered — the financial support the deceased would have provided, the companionship and guidance lost, and the conscious pain and suffering the deceased endured between injury and death.
State law governs these damage categories, and they vary. Texas, where the bankruptcy was filed, imposes no cap on compensatory damages in toxic-tort cases and applies a modified comparative-negligence standard with a fifty-one percent bar — meaning the plaintiff’s recovery is reduced by their share of fault but is not barred unless they are more than fifty percent at fault. Punitive damages in Texas are subject to statutory limitations. Each claimant’s own state law — the state where they were exposed, diagnosed, or reside — governs their individual tort claims against non-debtor defendants, and those rules differ.
The Insurance Playbook: What Defendants Will Try and How to Answer
The companies that made and sold cosmetic talc products have been defending these cases for years. They have a playbook. Knowing it in advance is your protection.
Play one: “Our product never contained asbestos.” The manufacturer will argue that its talc was tested and was asbestos-free, or that the specific product the claimant used came from an asbestos-free source. The counter is product-specific testing: if retained samples of the actual product can be tested with transmission electron microscopy, the fibers either are there or they are not. Where no retained sample exists, the supply chain documentation — sourcing records, mining origin, geological data — can establish that the talc came from a formation known for asbestos co-occurrence. Internal corporate testing records, obtained in discovery, may reveal that the company’s own tests detected asbestos — sometimes decades before it warned anyone.
Play two: “You cannot prove you used our specific product.” Decades have passed. The bottle was thrown away. The store is closed. The receipt is gone. The defense argues the claimant cannot identify which product caused the exposure. The counter is exposure reconstruction: family members who can testify to decades of daily use, photographs that show the product in the home, purchase patterns established through credit card or loyalty-program records, and the distinctive packaging and scent of specific brands that make them memorable even after decades. Co-worker affidavits, bathroom cabinet inventories, and the claimant’s own detailed exposure history — taken early, while memory is freshest — are the proof.
Play three: “Your cancer was caused by something else.” For mesothelioma, this play is weaker — mesothelioma is so asbestos-specific that the disease itself is near-conclusive evidence of asbestos exposure. But the defense will argue the exposure came from a different source: occupational asbestos exposure, home renovation exposure, or a different talc product. For ovarian cancer, this play is stronger — the defense will point to genetics, hormonal factors, obesity, reproductive history, and other environmental exposures. The counter is specific causation testimony from a board-certified oncologist who can perform a differential diagnosis and testify, to a reasonable degree of medical probability, that cosmetic talc exposure was a substantial contributing factor.
Play four: “The statute of limitations has expired.” The defense will argue that the claimant knew or should have known about the connection between their disease and talc earlier than they claim, and that the filing deadline has passed. This is why the discovery rule is so critical — and why the date of diagnosis, not the date of exposure, is the anchor. The counter is the medical record itself: when was the diagnosis made, when was the talc connection first discussed, and what did the claimant’s treating physicians know and when. Toxic tort cases nationwide generally follow the discovery rule, but the specific formulation varies by state, and some states impose an outer statute of repose that can cut off a claim even before discovery. This is a question that must be answered for the reader’s specific state — it cannot be generalized.
Play five: “The bankruptcy trust is your only remedy.” This is the most dangerous play because it is designed to make the claimant stop looking. The trust covers Miyoshi America. It does not cover the downstream manufacturers, the mining companies, or the retailers. The trust is one remedy. It is not the only remedy. A release signed with the trust may or may not affect claims against other defendants — and understanding exactly what a release covers before signing it is the difference between preserving a full recovery and accidentally surrendering it.
Play six: the fast settlement offer. An insurer may offer a quick, modest settlement — sometimes before the full scope of the disease and the full defendant map is known. The offer is designed to close the file cheaply before the claimant’s attorney has identified every liable party and every source of coverage. The counter is patience and thoroughness: identify every defendant, map every insurance policy, and build the full damages picture before any release is signed. A quick check from one defendant that releases all defendants is the most expensive money a family will ever accept.
The Law: Your Rights, Deadlines, and the Bankruptcy Structure
The Miyoshi trust was confirmed under Chapter 11 of the United States Bankruptcy Code in a Texas federal bankruptcy court. The channeling injunction that directs all current and future Miyoshi talc claims to the trust draws on principles analogous to Section 524(g) of the Bankruptcy Code — the provision Congress created specifically for asbestos-trust structures. But this is a novel extension: Section 524(g) was written for traditional asbestos manufacturers, not cosmetic talc suppliers. The Miyoshi trust is the first time these mechanics have been applied to a talc case through a prepackaged reorganization.
The trust structure includes a future claimants representative — a person appointed by the court whose sole function is to protect the interests of people who are not yet diagnosed but will be in the future. This is a due-process requirement: the bankruptcy cannot extinguish the rights of future claimants without giving them a voice. The representative participated in the six months of negotiations, and the confirmed plan includes provisions for future claimants to draw from the same twenty-million-dollar pool.
For individual tort claims against non-debtor defendants — the downstream manufacturers, the mining companies, the retailers — the governing law is the law of each claimant’s state. The bankruptcy does not change state tort law. A person diagnosed in Texas with mesothelioma from cosmetic talc exposure sues the non-debtor manufacturers under Texas product-liability law. A person diagnosed in New York sues under New York law. The choice of venue, the applicable standards, and the available damages all depend on where the claim arises.
Texas personal injury law provides a two-year statute of limitations from the date the cause of action accrues — and under the discovery rule, accrual occurs when the plaintiff knew or should have known of the injury and its cause. For mesothelioma, that is typically the date of diagnosis. Texas applies a modified comparative-negligence standard with a fifty-one percent bar, meaning the plaintiff’s recovery is reduced by their percentage of fault but is not barred unless they are more than fifty percent at fault. Texas imposes no cap on compensatory damages in toxic-tort cases, though punitive damages are subject to statutory limitations.
But most claimants in this trust are not in Texas. The trust administers claims from diagnosed individuals across all fifty states. Each claimant must assess the specific product-identification, exposure, and causation requirements of their own jurisdiction, as well as any applicable tort-reform provisions that may affect recovery. The two-year SOL is common but not universal — some states allow more time, some less, and the discovery rule’s specific formulation varies. A claimant in one state may have a deadline that runs from the date of diagnosis; a claimant in another may have a deadline that runs from the date they first suspected the connection. Some states have statutes of repose that impose an outer deadline regardless of discovery. This is why consulting an attorney in the reader’s state — early — is not a luxury but a necessity.
The bankruptcy venue — the Southern District of Texas in Houston — has emerged as a dominant forum for complex mass-tort Chapter 11 reorganizations, due in part to its specialized business bankruptcy bench and its experience with asbestos-trust structures. The strategic choice of a Texas bankruptcy venue likely reflects judicial familiarity with the trust mechanics and the court’s track record managing consensual mass-tort restructurings. But the bankruptcy venue does not determine where individual tort claims against non-debtor defendants must be filed — those claims proceed in the courts of the states where they arise.
How a Case Is Actually Built
Here is the chronological walk of a cosmetic talc case, from the first phone call to resolution. This is what the work looks like — not the brochure version, but the real version.
Week one: the intake and the freeze. The first conversation is about the diagnosis, the exposure history, and the timeline. What products did the claimant use? What brands? What years? How often? Where were they purchased? Who else was in the household and can corroborate? The medical records are ordered — the pathology report, the imaging, the treatment plan. And the preservation letters go out — not to Miyoshi (the trust handles that) but to every downstream manufacturer identified in the exposure history, demanding that they freeze formulation records, ingredient sourcing documents, internal testing data, and any corporate communications related to asbestos contamination. These letters are the first shot. They create a legal duty to preserve evidence that, if violated, gives the jury the right to assume the destroyed records were damaging.
Weeks two through eight: exposure reconstruction. The claimant’s exposure history is built in detail — not just “I used baby powder” but which brand, which size, which stores, which decades, how many times per day, and where on the body it was applied. Family members are interviewed. Old photographs are reviewed — a photo of a bathroom counter from 1985 that shows a specific brand of body powder is evidence. Purchase records, where they survive, are pulled. The exposure history is the foundation of the product-identification case, and it has to be built while the claimant and their witnesses can still remember.
Months two through six: expert assembly and causation. The case needs a team of experts. A geologist who specializes in talc-asbestos co-occurrence and can testify about the geological source of the talc in the identified products. An industrial hygienist who can reconstruct the exposure — how many fibers were released per application, how many were inhaled, what the cumulative dose was over decades of use. A board-certified pathologist who can analyze tissue samples for asbestos fiber burden — the actual fibers in the patient’s body, counted and typed under electron microscopy. An oncologist who can testify to general and specific causation — that cosmetic talc exposure was a substantial contributing factor in causing this specific patient’s mesothelioma or ovarian cancer. And a life-care planner who can project the lifetime cost of treatment, lost earning capacity, and the care the patient will need as the disease progresses.
Months three through twelve: discovery. Once the lawsuits are filed against the non-debtor defendants, discovery begins. The manufacturers are compelled to produce their formulation records, their ingredient sourcing documents, their internal testing data, their communications with Miyoshi and other suppliers, and their corporate knowledge of asbestos contamination risks. Depositions are taken — of the corporate representatives who decided whether to test the talc, of the quality-control managers who approved or rejected batches, of the executives who decided whether to warn consumers. The internal documents that emerge in discovery are where the case is won or lost — the memo from 1987 that says “our talc contains trace asbestos,” the email from 2005 that says “we should consider switching to asbestos-free sources,” the meeting minutes where the cost of testing was weighed against the cost of a warning label.
Months six through eighteen: the trust claim and the tort claims in parallel. The trust claim is filed — with a detailed proof-of-claim package including the exposure history, the product-identification evidence, the pathology reports, and the medical records. The trust’s distribution procedures are not yet finalized, so the claim is queued. Meanwhile, the tort litigation against the non-debtor defendants proceeds. Mediation may be appropriate for claims against solvent defendants who recognize their exposure and want to resolve the case short of trial. Settlement demands are structured to reflect the full tort value of the case — not the trust’s fractional payout.
Trial. If the case does not settle, it goes to trial. The jury hears the exposure history, the expert testimony, the internal corporate documents, and the medicine. The jury decides whether the manufacturer’s product caused the claimant’s disease and what the harm is worth. In mesothelioma cases, the verdicts can be substantial — eight figures in favorable venues with strong product identification and evidence of corporate knowledge. In ovarian cancer cases, the results vary more widely, but significant verdicts have been returned against talc manufacturers.
The number at the end of the case is built from all of this — the preserved evidence, the expert testimony, the corporate documents, the exposure history, and the medical record. It is not a windfall. It is the measured compensation for a life destroyed by a product that should have been tested, should have been warned about, and was not.
Your First Steps: A Practical Roadmap
If you or someone you love has been diagnosed with mesothelioma or ovarian cancer and has a history of using cosmetic talc products, here is what to do — and what not to do — in the first days and weeks.
Medical care comes first. Nothing on this page matters more than your treatment. Follow your oncologist’s plan. Get the second opinion. Begin the chemotherapy, the surgery, the radiation — whatever the standard of care calls for. The legal case exists to serve the medical reality, not the other way around.
Write down the product history now. While memory is available — and while the patient, if they are still able, can contribute — write down every talc-containing product the patient used, the brand, the approximate years of use, how often it was applied, and where on the body. This is not a guess. This is the foundation of the product-identification case, and it is far easier to build while the patient and their family can still provide detail. Take photographs of any remaining product containers, lot numbers, and packaging. Do not dispose of any remaining product.
Do not sign anything from the trust or any defendant without legal review. A release is a legal document that may extinguish your right to pursue every other defendant in the supply chain. A trust claim form, a settlement offer from a manufacturer, a “release of all claims” — each of these may be perfectly appropriate or catastrophically premature, and the difference depends on whether every liable party has been identified and every source of coverage has been mapped. Signing before that analysis is complete is the single most common way families lose the full value of their case.
Do not give a recorded statement to any insurance company. An adjuster may call, express sympathy, and ask for “just a brief statement about what happened.” The statement is recorded. It is designed to lock the claimant into a version of events before the full exposure history has been reconstructed and before counsel has identified every defendant. The appropriate response is: “I am not prepared to give a recorded statement at this time. Please contact my attorney.”
Contact an attorney. Not next month. Not after the treatment plan is settled. Now — because the evidence clock is running. The preservation letters that freeze corporate documents should go out while the records still exist. The exposure history should be taken while the patient can still provide it. And the trust claim should be filed promptly, because the twenty-million-dollar pool is finite and future claimants will draw from the same fund, potentially reducing the payment percentage over time.
We offer a free consultation, twenty-four hours a day, seven days a week, with live staff — not an answering service. Call us at 1-888-ATTY-911 or reach us through our contact page. We work on contingency: we do not get paid unless we win your case. Past results depend on the facts of each case and do not guarantee future outcomes.
Frequently Asked Questions
Can I still file a claim if I used talc products decades ago?
Yes. The discovery rule — which applies in most states to toxic-tort claims — generally starts the statute-of-limitations clock when you discovered or should have discovered your injury and its cause, not when you were exposed to the product. For mesothelioma, that is typically the date of diagnosis. For ovarian cancer, the analysis is similar but can involve additional questions about when the talc connection was or should have been identified. Mesothelioma has a latency of twenty to fifty years between exposure and diagnosis, so the vast majority of cosmetic talc cases involve products used decades ago — and the law accounts for that delay through the discovery rule. However, each state has its own formulation of the discovery rule, and some states impose a statute of repose that creates an outer deadline regardless of when the disease was discovered. You need an attorney in your state to confirm the specific deadline.
Is the $20 million trust my only option for compensation?
No — and this may be the most important thing on this page. The trust covers claims against Miyoshi America, the ingredient supplier. It does not cover claims against the downstream manufacturers that made the finished products, the mining companies that extracted the talc, or the retailers that sold the products. Those entities are not in bankruptcy, their liability was not discharged, and they remain fully suable in court. The trust is one avenue of compensation. Litigation against solvent non-debtor defendants is a separate — and often far more valuable — avenue. A comprehensive case strategy pursues both in parallel: the trust claim to secure a distribution from the finite pool, and the tort litigation to seek full compensation from every liable party.
How much will I receive from the Miyoshi trust?
The trust’s payment percentage and claims matrix have not yet been finalized. Based on comparable asbestos-trust structures, trust payouts typically represent five to twenty-five percent of the liquidated claim value — meaning a claim liquidated at one million dollars might produce a trust payment of fifty thousand to two hundred and fifty thousand dollars. The twenty-million-dollar pool is shared among all current and future claimants, so the payment percentage may decline over time as additional claims are filed. Filing the trust claim promptly secures a distribution position before the fund is further diluted. The trust is a floor, not a ceiling — the full value of the case may come from litigation against solvent defendants who are not in bankruptcy.
Do I need a lawyer to file a trust claim?
You are not legally required to have a lawyer to file a trust claim, but proceeding without one is risky. The trust claim form requires detailed exposure histories, product-identification evidence, pathology reports, and medical records — and the quality and completeness of that submission affects how the claim is classified in the trust’s payment matrix. More importantly, filing a trust claim without first conducting a full supply-chain analysis may result in signing a release that forecloses claims against other, far more valuable defendants. An attorney who handles toxic-tort cases can ensure the trust claim is filed properly while simultaneously identifying and pursuing every other liable party.
What if I do not know which specific talc product I used?
This is a common challenge in cosmetic talc cases, given the decades-long latency of mesothelioma and ovarian cancer. Product identification is built through exposure reconstruction: detailed interviews with the patient and family members, review of old photographs that may show product containers in the home, purchase patterns established through historical records, and the distinctive branding and packaging of specific products that make them memorable even after decades. The legal standard for product identification varies by state — some jurisdictions require identification of a specific product, while others allow recovery based on identification of a product category or a general exposure pattern. This is a core issue in every cosmetic talc case, and it is one of the first things an experienced attorney will work on.
Can I file a claim if my loved one has already died?
Yes. If your family member died from mesothelioma or ovarian cancer and had a history of cosmetic talc use, the estate and the statutory beneficiaries may bring wrongful-death and survival claims. A personal representative — the person the court authorizes to bring the family’s case — is appointed, and the claims proceed on behalf of the estate and the surviving family members. The damages in a wrongful-death case include the financial support the deceased would have provided, the companionship and guidance lost, and the conscious pain and suffering the deceased endured between diagnosis and death. The deadline for filing a wrongful-death claim is governed by the same state-law statute of limitations that applies to the underlying injury — typically two years from the date of death in states with a two-year SOL, though the discovery rule may affect the accrual date if the connection to talc was not known at the time of death.
What if I was exposed to asbestos at work AND through cosmetic talc?
Mesothelioma can be caused by cumulative asbestos exposure from multiple sources. A person who had occupational asbestos exposure — at a refinery, a shipyard, a construction site, or through automotive brake work — and also used cosmetic talc products may have claims against both the occupational defendants and the cosmetic-talcm defendants. The occupational exposure does not eliminate the cosmetic-talc claim; it complicates the causation analysis but does not defeat it. The defense will argue that the occupational exposure was the sole cause, but the plaintiff’s experts can testify that each significant exposure contributed to the cumulative dose that caused the disease. A full exposure history — occupational and consumer — is essential to identify every liable party.
How long does a talc litigation case take?
The timeline varies depending on the complexity of the case, the number of defendants, the jurisdiction, and whether the case settles or goes to trial. Trust claims can be processed within months of the trust’s distribution procedures being finalized, though payment may take longer depending on the trust’s payment schedule. Tort litigation against non-debtor defendants typically takes eighteen months to three years from filing to resolution — though mesothelioma cases are often expedited by courts because of the patient’s limited life expectancy, and many courts have rules that allow for accelerated trial settings in terminal-disease cases. Some cases settle within months of filing; others require full discovery, expert depositions, and trial preparation before resolution.
What does it cost to hire an attorney for a talc case?
Our firm works on contingency. We charge thirty-three and a third percent of the recovery before trial and forty percent if the case goes to trial. We do not get paid unless we win your case. The consultation is free. There are no hourly charges and no upfront fees. The costs of the case — expert witnesses, filing fees, record retrieval, depositions — are typically advanced by the firm and recovered from the settlement or verdict. This means that the quality of the legal representation does not depend on the family’s ability to pay upfront; it depends on the strength of the case. You can learn more about how contingency fees work in this video explanation.
Why This Firm
Ralph Manginello has spent twenty-seven-plus years in courtrooms, including federal court in the Southern District of Texas — the same district where the Miyoshi trust was confirmed. He was a journalist before he was a lawyer, which means he reads documents the way a reporter reads them: looking for the sentence the author did not want you to find. He is a member of the Texas Trial Lawyers Association and the Houston Bar Association, admitted to practice in Texas state courts and the United States District Court for the Southern District of Texas. He has tried cases involving catastrophic injury and wrongful death for more than two decades, and he approaches every file with the conviction that the company’s own documents — its testing records, its internal communications, its safety decisions — are the most powerful evidence in the case.
Lupe Peña spent years as an insurance-defense attorney at a national defense firm — the rooms where adjusters and their software decided how to value, deny, and devalue claims exactly like yours. He sat across the table from the people who wrote the playbook described above. He knows how reserves are set in the first forty-eight hours, how recorded statements are engineered, how valuation software discounts injuries it cannot see, and how the quick settlement check arrives with a release printed on the back before the medical results are in. He now sits on your side of the table. Lupe is fluent in Spanish — he conducts full client consultations in Spanish without an interpreter — and our staff is bilingual.
We are Attorney911 — The Manginello Law Firm, PLLC. We are based in Houston, Texas, with offices in Austin and Beaumont, and we take toxic-tort and catastrophic-injury cases across Texas and nationwide, working with local counsel where required. We have recovered more than fifty million dollars for our clients over our firm’s history. We are available twenty-four hours a day, seven days a week, with live staff — not an answering service. When you call, a person answers.
Hablamos Español. We serve your family fully in Spanish.
If you or someone you love has been diagnosed with mesothelioma or ovarian cancer and has a history of using cosmetic talc products — body powders, baby powders, face powders, makeup containing talc — call us at 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case. The evidence clock is running. The trust is accepting claims. And the companies that made the products you used are still answerable — if someone moves fast enough to hold them.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting the firm is free and confidential. Call 1-888-ATTY-911, twenty-four hours a day, seven days a week.